Cystadrops (Cysteamine HCl) Patent Expiration, LOE Window & CMS Spending

Cystadrops (Cysteamine HCl) by Recordati Rare Diseases: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $10.9M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRecordati Rare Diseases
FDA Application & PathwayN211302 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$10.9M
2024 Medicare Part D Spend$2.7M
2024 Medicaid Spend$8.2M
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 29.7% 2-yr change)